Throughout August 2023, the Office of Information and Regulatory Affairs, Office of Management and Budget, Executive Office of the President, also known as “OIRA”, has engaged in a flurry of stakeholder meetings. The discussion of these meetings revolves around a proposed rule with the potential to significantly reshape FDA’s regulations. If implemented, the rule would clearly state that laboratory developed tests (“LDTs”) are legally recognized as devices under the Federal Food, Drug, and Cosmetic Act.
The attendance of these stakeholder meetings encapsulate diverse entities who are beneficiaries of this rule, thus carefully following its evolution. These meetings’ importance is heightened by the increasingly apparent role LDTs play in several scientific and medical contexts.
The meetings signify the ongoing efforts of OIRA to solicit feedback and viewpoints on the proposed modifications from various stakeholders. The consensus – or lack of – arising from these discussions will shape the final form of the proposed rule.
The next stakeholder meeting discussing this proposed rule is scheduled for September 6, ensuring the discussion and analysis continues within these crucial sectors. At this point, it is insightful for legal professionals to keep abreast with the proceedings and potential rulings on labelling LDTs as devices. The implications of such a change for the medical, scientific and regulatory landscape are far-reaching.
- How will the inclusion of LDTs as ‘devices’ change the way they are regulated?
- What are the potential implications for the biotechnology and pharmaceutical sectors?
- Will this shift cause ripple effects on IP rights and patents across the medical industry?
With the situation remaining fluid, legal professionals with a stake in these developments must ensure that they remain updated on the proceedings. The discourse generated from these meetings serves as a testament to OIRA’s commitment in refining a proposal that has the promise to redefine the purview of the Federal Food, Drug, and Cosmetic Act. For each entity concerned, the proposed rule’s final shape will potentially impact their regulatory compliance requirements and operating procedures.